Quantcast
Home > Quotes > LIFE
LIFE

aTyr Pharma, Inc. Common Stock (LIFE) Quote & Summary Data

$0.505
*  
0.0531
9.51%
Get LIFE Alerts
*Delayed - data as of Mar. 25, 2019  -  Find a broker to begin trading LIFE now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
0.875
Today's High / Low
$ 0.5935 / $ 0.5019
Share Volume
2,051,930
50 Day Avg. Daily Volume
295,778
Previous Close
$ 0.5581
52 Week High / Low
$ 3.05 / $ 0.3751
Market Cap
15,161,889
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.01

Intraday Chart

Shares Traded

Share Volume:
2,051,930
50 Day Avg. Daily Volume:
295,778

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
Earnings Per Share (EPS):
$ -1.34

Trading Range

The current last sale of $0.505 is 34.63% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.5935 $ 3.05
 Low: $ 0.5019 $ 0.3751

Company Description (as filed with the SEC)

aTyr Pharma is a clinical-stage biotechnology company engaged in the discovery and clinical development of innovative medicines using its knowledge of tRNA synthetase biology. We have discovered novel extracellular functions of proteins derived from a number of tRNA synthetase genes, a family of more than 20 genes that influence immune function, and other activities, in previously unknown ways. Built on more than a decade of foundational science on extracellular tRNA synthetase biology and its effect on immune responses, we have built a global intellectual property estate directed to all 20 human tRNA synthetases as well as our product candidates. Today, we focus on the therapeutic translation of the Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase (HARS) gene family, which has fueled a pipeline of novel drug candidate programs addressing disease areas of high unmet medical need, including cancer and lung disease.  ... More ...  



Risk Grade

Where does LIFE fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.555
Open Date:
Mar. 25, 2019
Close Price:
$ 0.51
Close Date:
Mar. 25, 2019


Consensus Recommendation

Analyst Info